NANJING, China, Nov. 23, 2023 /PRNewswire/ -- The 6th China International Import Expo (CIIE) was held in Shanghai, China on November 5, 2023. Nanjing IASO Biotechnology Co., Ltd. (IASO Bio) made its debut at the CIIE with FUCASO, the world's first fully-human CAR-T, and entered into a strategic partnership with several international medical institutions, bringing hope for a cure to multiple myeloma (MM) patients worldwide. As a biopharmaceutical company that engages in the R&D, production and sales of innovative cell drugs, IASO Bio is not only developing CAR-T therapies of international standards for Chinese patients, but also actively promoting international clinical trials, demonstrating its scientific research and innovation capabilities.
The world's first fully-human CAR-T makes a significant debut
On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCASO) for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM). Meanwhile, the Equecabtagene Autoleucel Injection has received the Orphan Drug Designation, as well as the Regenerative Medicine Advanced Therapy and Fast Track Designations from the U.S. Food and Drug Administration, and has been approved for clinical trials in the United States.
A single infusion of FUCASO can lead to lasting and deep remission with a favorable safety profile in patients with R/R MM who have failed multiple lines of therapy. Thanks to its unique design, FUCASO, as a fully-human CAR-T therapy, is able to persist in patients for a longer period of time, offering hope for overcoming the challenging problem of relapsed MM.
Establishing an international CAR-T diagnostic and treatment center
FUCASO has attracted patients from numerous countries around the world, including Asia, Europe, Oceania, and Africa, to come to China for treatment in just 4 months since its approval for marketing in China. Many patients in the first batch were accompanied by primary drug resistance, multiple drug resistance, and cytogenetically high risk, and after the treatment with FUCASO, they achieved complete remission and minimal residual disease negativity.
At present, several authoritative hematological malignancy treatment hospitals in China have established certified FUCASO treatment centers, and are recognized globally for their leading level of full-process management of CAR-T treatment. It is noteworthy that the cost of treatment with FUCASO in China is significantly lower than that of similar products in Europe and America, which has enhanced the accessibility of this innovative drug and benefited MM patients worldwide.
In addition, IASO Bio has established strategic partnerships with a number of international medical institutions to jointly build an international CAR-T diagnostic and treatment center to serve patients worldwide.